A new analysis reported by Medscape suggests that elevated levels of a serum protein called regenerating islet-derived 3-alpha (REG3-alpha) are linked to a greater likelihood of disease progression in people who go on to develop Crohn’s disease (CD), with raised levels detectable years before diagnosis. The finding points to a potential early warning marker for clinicians managing at-risk patients.
Crohn’s disease is a form of inflammatory bowel disease (IBD) characterised by chronic inflammation that can affect any part of the digestive tract, often leading to complications such as strictures, fistulas or the need for surgery over time. Identifying which patients are likely to follow a more complicated disease course remains a persistent challenge in gastroenterology, as current diagnostic tools typically detect disease only once symptoms and inflammation are already established. Researchers have long sought blood-based biomarkers that could flag high-risk individuals earlier, allowing for closer monitoring or more tailored management strategies before structural damage occurs.
According to the reporting, investigators found that people who later developed complicated Crohn’s disease, meaning disease involving strictures, penetrating complications or surgical intervention, had higher circulating levels of REG3-alpha measured well in advance of their formal diagnosis. REG3-alpha is a protein linked to gut epithelial defence and has previously been studied in the context of intestinal inflammation. The association held when comparing patients whose disease later became complicated against those whose Crohn’s disease followed a milder course. The authors framed this as evidence that biological changes associated with more aggressive disease may be measurable in the blood years before clinical symptoms prompt a diagnostic work-up. The findings add to a growing body of research examining pre-diagnostic biomarkers in Crohn’s disease, an area of interest given the long-recognised delay between the onset of underlying gut inflammation and the point at which patients typically present with recognisable symptoms.
For clinicians and researchers in IBD, a validated pre-diagnostic biomarker of this kind could eventually support earlier risk stratification, helping identify patients who might benefit from closer follow-up or more proactive management before complications develop. This is particularly relevant for people with a family history of Crohn’s disease or those under investigation for gastrointestinal symptoms, where earlier identification of a higher-risk biological profile could inform monitoring decisions. The source material does not indicate that REG3-alpha testing is yet used in routine clinical practice, and further validation would be expected before any such marker could be incorporated into standard diagnostic pathways.
Reference
Medscape. Serum protein can flag complicated CD years before diagnosis. Medscape. 2026. Available from: https://www.medscape.com/viewarticle/serum-protein-can-flag-complicated-crohns-disease-years-2026a1000z60
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.